The future EU funding landscape - maximising NHS opportunities

Chair: Michael Woods
European Policy Manager - NHS European Office, NHS Confederation

Octavio Pernas
FP7UK National Contact Point for Health, Beta Technology on Behalf of TBS
Session delivered by the European Office

The future EU funding landscape

Dr Octavio Pernas
FP7UK National Contact Point for Health
Agenda

• What’s on the Horizon
• Facts and figures
• NCP support
Agenda

- What’s on the Horizon
- Facts and figures
- NCP support
EU funding for Research and Innovation

- Competitiveness and Innovation Programme (CIP)
- Framework Programme (Horizon 2020)
- Health Programme
- European & Developing Countries Clinical Trials Partnership (EDCTP)
- Structural Funds
- Joint Technology Initiatives
- Ambient Assisted Living
- Other schemes
THE FRAMEWORK PROGRAMME FOR RESEARCH AND INNOVATION

HORIZON 2020
Horizon 2020 - summary

• Commission proposal for a 80 billion euro research and innovation funding programme (2014-2020)

• A core part of Europe 2020, Innovation Union & European Research Area:
  • Responding to the economic crisis to invest in future jobs and growth
  • Addressing people’s concerns about their livelihoods, safety and environment
  • Strengthening the EU’s global position in research, innovation and technology
Horizon 2020 – what is new?

• A single programme bringing together three separate programmes/initiatives (FP, EIT, CIP)
• More support for innovation activities
• Continuation of investment in frontier research
• International cooperation
• More simplification
Horizon 2020 – simplification

- Single set of simpler and more coherent participation rules.
- Moving from several funding rates for different beneficiaries and activities to just two.
- Replacing the four methods to calculate overhead or "indirect costs" with a single flat rate.
- Major simplification under the forthcoming financial regulation
- Successful applicants to get working more quickly: reduction of average time to grant by 100 days (currently 350 days)
Horizon 2020 – three priorities

1. Excellent science
2. Industrial leadership
3. Societal challenges
Industrial Leadership
- Leadership in enabling and industrial technologies
- Access to risk finance
- Innovation in SMEs

Societal Challenges
- Health, demographic change and well-being
- Food security, sustainable agriculture, marine and maritime research, and the bio-economy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and secure societies
- EIT

Excellent Science
- European Research Council (ERC)
- Future and Emerging Technologies (FET)
- Marie Curie Actions
- Research infrastructures

Shared objectives and principles

Common rules, toolkit of funding schemes
## Horizon 2020 – Excellent science

**Indicative Budget (€ billion) ~32% of H2020**

<table>
<thead>
<tr>
<th>Category</th>
<th>Budget (€ billion)</th>
</tr>
</thead>
<tbody>
<tr>
<td>European Research Council</td>
<td>13.3</td>
</tr>
<tr>
<td>Frontier research by the best individual teams</td>
<td></td>
</tr>
<tr>
<td>Future and Emerging Technologies</td>
<td>3.1</td>
</tr>
<tr>
<td>Collaborative research to open new fields of innovation</td>
<td></td>
</tr>
<tr>
<td>Marie Curie actions</td>
<td>5.6</td>
</tr>
<tr>
<td>Opportunities for training and career development</td>
<td></td>
</tr>
<tr>
<td>Research infrastructures (including e-infrastructure)</td>
<td>2.5</td>
</tr>
<tr>
<td>Ensuring access to world-class facilities</td>
<td></td>
</tr>
</tbody>
</table>
Horizon 2020 – Industrial leadership

<table>
<thead>
<tr>
<th>Leadership in enabling and industrial technologies</th>
<th>13.8</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICT, nanotechnologies, materials, biotechnology, manufacturing, space</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Access to risk finance</th>
<th>3.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leveraging private finance and venture capital for research and innovation</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Innovation in SMEs</th>
<th>0.7 complemented by 20% of societal challenges and industrial leadership and ‘access to risk finance’ with strong SME focus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fostering all forms of innovation in all types of SMEs</td>
<td></td>
</tr>
</tbody>
</table>
## Horizon 2020 – Societal challenges

<table>
<thead>
<tr>
<th>Challenge</th>
<th>Budget (€ billion)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health, demographic change and wellbeing</td>
<td>8.0</td>
</tr>
<tr>
<td>Food security, sustainable agriculture &amp; the bioeconomy</td>
<td>4.2</td>
</tr>
<tr>
<td>Secure, clean and efficient energy (ex ITER and other nuclear under Euratom Treaty)</td>
<td>5.8</td>
</tr>
<tr>
<td>Smart, green and integrated transport</td>
<td>6.8</td>
</tr>
<tr>
<td>Climate action, resource efficiency and raw materials</td>
<td>3.2</td>
</tr>
<tr>
<td>Inclusive, innovative and secure societies</td>
<td>3.8</td>
</tr>
</tbody>
</table>

Indicative Budget (€ billion) ~40% of H2020
Horizon 2020 – opportunities for the NHS

- Better planning (work programmes for 2+1 years)
- More support for research infrastructures, public-private and public-public partnerships
- Translational approaches, integrating several steps of the innovation process in the health care area.
- More support for clinical trials: “Effective sharing of data is essential, as is the translation of research findings into the clinic, in particular through the conduct of clinical trials“
- More “patient-focused” priorities
Horizon 2020 – Health challenge

Indicative priorities

1. Understanding health, wellbeing and disease
   1.1. Understanding the determinants of health, improving health promotion and disease prevention
   1.2. Understanding disease
   1.3. Improving surveillance and preparedness

2. Preventing disease
   2.1. Developing effective prevention and screening programmes and improving the assessment of disease susceptibility
   2.2. Improving diagnosis and prognosis
   2.3. Developing better preventive and therapeutical vaccines

Horizon 2020 – Health challenge

Indicative priorities

3. Treating and managing disease
   3.1. Treating disease, including developing regenerative medicine
   3.2. Transferring knowledge to clinical practice and scalable innovation actions

4. Active ageing and self-management of health
   4.1. Active ageing, independent and assisted living
   4.2. Individual awareness and empowerment for self-management of health

Horizon 2020 – Health challenge

Indicative priorities

5. Methods and data
5.1. Improving health information and better use of health data
5.2. Improving scientific tools and methods to support policy making and regulatory needs
5.3. Using in-silico medicine for improving disease management and prediction

6. Health care provision and integrated care
6.1. Promoting integrated care
6.2. Optimising the efficiency and effectiveness of healthcare provision

Horizon 2020 – next steps

- Summer 2013: Draft first work programme
- Autumn 2013: Inter-service consultation and consultation of the Member States
- December 2013: Adoption of the work programme and publication of the calls for proposals
Agenda

• What’s on the Horizon
• Facts and figures
• NCP support
## Facts and figures – FP7 Health

### Overall Summary

<table>
<thead>
<tr>
<th>Year</th>
<th>Total Funding</th>
<th>Projects Funded</th>
<th>Topics</th>
<th>SME Targeted</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>€641 million</td>
<td>153</td>
<td>87</td>
<td>0%</td>
</tr>
<tr>
<td>2008</td>
<td>€577 million</td>
<td>172</td>
<td>87</td>
<td>0%</td>
</tr>
<tr>
<td>2009</td>
<td>€593 million</td>
<td>108</td>
<td>71</td>
<td>0%</td>
</tr>
<tr>
<td>2010</td>
<td>€628 million</td>
<td>131</td>
<td>72</td>
<td>0%</td>
</tr>
<tr>
<td>2011</td>
<td>€657 million</td>
<td>124</td>
<td>51</td>
<td>20%</td>
</tr>
<tr>
<td>2012</td>
<td>€657 million</td>
<td>140</td>
<td>37</td>
<td>53%</td>
</tr>
<tr>
<td>2013</td>
<td>€819 million*</td>
<td>~143</td>
<td>37</td>
<td>55%</td>
</tr>
</tbody>
</table>
Facts and figures – FP7 Health

Participants

UK has highest level of participation in successful health projects
UK organisations have secured > €550 million of EU funding for Health research
Facts and figures – FP7 Health
Participants landscape (UK) – academia and NHS

% 100

HEI NHS

2010 2011 2012
Facts and figures – FP7 Health

EC Contribution landscape (UK) – academia and NHS
FP7 Health – NHS participants

Brighton and Sussex University Hospitals

Guy’s and St Thomas’ NHS Foundation Trust

King’s College Hospital NHS Foundation Trust

The Royal Liverpool and Broadgreen University Hospitals NHS Trust

Moorfields Eye Hospital NHS Foundation Trust

Gloucestershire Hospitals NHS Foundation Trust

Great Ormond Street Hospital for Children NHS Foundation Trust

The Christie NHS Foundation Trust

Oxford University Hospitals NHS Trust

Blood and Transplant

University College London Hospitals NHS Foundation Trust

Royal Brompton & Harefield NHS Foundation Trust

NICE National Institute for Health and Care Excellence
Facts and figures – FP7 Health

NHS Case study

• 13 partners from 7 EU countries, including: 4 Hospitals, 3 Universities, 3 SMEs, 2 Patient Organisations, 1 Pharmaceutical Company

• Funded under call FP7-HEALTH-2012-INNOVATION-1: EC contribution of approximately €8 million

• Execution: from November 2012 to April 2018

• Assessment of nitisinone for use in treating alkaptonuria. It could be the first effective treatment for AKU patients.

• Coordinator: Royal Liverpool and Broadgreen University Hospitals NHS Trust
Facts and figures – FP7 Health

NHS Case study

Evaluation: 15/15

1. S/T quality:
“The overall project is presented very clearly, in a systematic manner. The description perfectly addressed all relevant aspects of the call”.

2. Implementation:
“The project structure is well designed and appropriate. The parties involved are highly skilled, providing an excellent mix of scientific, strategic and operational skills”

3. Impact:
“The plans for dissemination were extremely well prepared. The IP Policy was seen as exemplary”
Agenda

• What’s on the Horizon
• Facts and figures
• NCP support
NCP support

- A UK-wide network provided by the Technology Strategy Board to help you engage with H2020
- General advice on H2020 participation – help you to make an informed decision (signposting)
- Helpline - scientific priorities, calls, participation rules, financial rules, partnering…
- Follow-on advice – negotiation stage, reports, cost claims, IPR, project management…
- Informing and Awareness Raising (Infodays, seminars,…)
- Looking for synergies with other entities (NHS EU office)

All advice is confidential, impartial and free
NCP support

https://connect.innovateuk.org/web/fp7uk/overview

Connect
• NCP contacts
• Information
• News
• Events
• Documents
• Network
Further information

- Participant portal: http://ec.europa.eu/research/participants/portal/page/home
- Fit for Health: http://www.fitforhealth.eu/
- Health project database: http://www.healthcompetence.eu
- Register as an expert: http://ec.europa.eu/research/participants/portal/page/experts
- _Connect: https://connect.innovateuk.org/web/fp7-uk-health
Further information

Health National Contact Point: Octavio Pernas

Website: https://connect.innovateuk.org/web/fp7-uk-health
E mail: octavio.pernas@tsb.gov.uk
Phone: 01302 322633
Mobile: 07775 584028
Twitter @FP7_Health_NCP

Alternative: Victoria Brewer
victoria.brewer@headoffice.mrc.co.uk
02073 952205